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ABSTRACT
Background
Despite recent successes with biological agents as therapy for autoimmune inflammatory
diseases such as rheumatoid arthritis (RA), many patients fail to respond adequately to these
treatments, making a continued search for new therapies extremely important. Recently, the
prevailing hypothesis that reactive oxygen species (ROS) promote inflammation was
challenged when polymorphisms in Ncf1, that decrease oxidative burst, were shown to
increase disease severity in mouse and rat arthritis models. Based on these findings we
developed a new therapy for arthritis using oxidative burst-inducing substances.
Methods and Findings
Treatment of rats with phytol (3,7,11,15-tetramethyl-2-hexadecene-1-ol) increased oxidative
burst in vivo and thereby corrected the effect of the genetic polymorphism in arthritis-prone
Ncf1
DA rats. Importantly, phytol treatment also decreased the autoimmune response and
ameliorated both the acute and chronic phases of arthritis. When compared to standard
therapies for RA, anti-tumour necrosis factor-a and methotrexate, phytol showed equally good
or better therapeutic properties. Finally, phytol mediated its effect within hours of
administration and involved modulation of T cell activation, as injection prevented adoptive
transfer of disease with arthritogenic T cells.
Conclusions
Treatment of arthritis with ROS-promoting substances such as phytol targets a newly
discovered pathway leading to autoimmune inflammatory disease and introduces a novel class
of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
The Editors’ Summary of this article follows the references.
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Rheumatoid arthritis (RA) is a complex chronic inﬂamma-
tory disease dependent on multiple interacting environ-
mental and genetic factors, making it difﬁcult to understand
its pathogenesis and thereby to ﬁnd effective therapies. The
therapy of RA is mainly based on methotrexate (MTX) and
biological agents that directly target molecules involved in
the pathogenesis of RA—e.g., the human soluble tumour
necrosis factor receptor etanercept (Enbrel). However,
cytokines targeted with such biological agents also play a
general role in the immune defence, and the risk of infections
increases with use of these agents [1]. Therefore, a continued
search for successful therapies for RA is extremely important.
Disease-causing mechanisms underlying RA that can be
targeted with a preventive or therapeutic treatment have
been difﬁcult to identify [2]. In addition, the search for genes
predisposing for autoimmunity has so far had limited success
[3–6]. Recently, neutrophil cytosolic factor 1 (Ncf1) was identiﬁed
by positional cloning as a gene controlling arthritis severity in
rats [7]. Ncf1 (alias p47phox) is an important subunit of the
NADPH oxidase complex responsible for the one-electron
reduction of oxygen that ultimately yields reactive oxygen
species (ROS) [8,9]. This oxidative burst process is used by
phagocytes primarily to kill invading pathogens [10]. The
surprising ﬁnding with the Ncf1 polymorphism in the
susceptible Dark Agouti (DA) rat was that increased suscept-
ibility to arthritis was associated with low oxidative burst
capacity [7], contradicting the hypothesis in current use that
high levels of free radicals promotes inﬂammation [11]. This
ﬁnding led us to propose that substances that increase the
activation of the NADPH oxidase complex could ameliorate
and possibly prevent severe arthritis. In this study we used
rats as an experimental model of RA to identify compounds
that increase oxidative burst capacity in vivo and investigate




Rats of strains DA and LEW.1F (Zentralinstitut fu ¨r
Versuchstierzucht, Hannover, Germany) were kept in a
climate-controlled environment with 12 h light/dark cycles,
housed in polystyrene cages containing wood shavings, and
fed standard rodent chow and water ad libitum in the animal
house of Medical Inﬂammation Research (http://www.inﬂam.
lu.se). The rats were found to be free from common
pathogens including Sendai virus, Hantaan virus, coronavi-
rus, reovirus, cytomegalovirus, and Mycoplasma pulmonalis. The
DA.Ncf1
E3 and DA.pia34 strains have been described [7,12].
The experiments were approved by local (Malmo ¨/Lund,
Sweden) ethical committee license M70/01 and M70/04.
Human Promyelocytes
The human promyelocyte line HL-60 (CCl-240; ATCC,
Manassas, Virginia, United States) was cultured in D-MEM
(Gibco, Paisley, UK) complemented with Hepes, 5% fetal calf
serum, and penicillin-streptomycin at standard cell culture
concentrations. The cells were differentiated to granulocytes
by culture in the presence of 1.25% DMSO (Sigma-Aldrich,
St. Louis, Missouri, United States) for 6 d [13]. Before they
were assayed the cells were washed and resuspended in D-PBS
(Gibco) to a concentration of 10
7 cells/ml.
Oxidative Burst Assay of Granulocytes In Vitro
Saturated alkane molecules (C8-C17) (Larodan Fine Chem-
icals AB, Malmo ¨, Sweden), pristane (2,6,10,14-tetramethyl-
pentadecane), and phytol (3,7,11,15-Tetramethyl-2-
hexadecen-1-ol) (all from Sigma-Aldrich) were tested for
oxidative burst-inducing capacity according to a previously
described method [14]. Oils were solubilized by dilution at
1%–5% concentration in 10% b-cyclodextrin (Sigma-Al-
drich) in PBS. b-cyclodextrin by itself had no stimulating
effect on ROS production. Brieﬂy, 5 ll of resuspended oils
were added to 96-well plates containing 5310
5 cells/well in a
total volume of 200 ll of PBS containing isoluminol and
horseradish peroxidase (ﬁnal isoluminol concentration 100
mg/ml; Sigma-Aldrich) and horseradish peroxidase type II (5
units/ml; Sigma-Aldrich). Samples were gently mixed and data
collection was initiated immediately. Extracellular ROS
production was followed at 37 8C as luminescence signal
(FluoStar Optima, BMG Labtechnologies, Offenburg, Ger-
many) and presented as maximal relative signal during a
measurement period of 30 min.
Induction and Evaluation of Arthritis
Disease was induced in all rats at the age of 6–12 wk. Rats
were sex- and age-matched within all experiments.
Pristane-induced arthritis (PIA) and oil-induced arthritis
was induced by a subcutaneous (SC) injection at the base of
the tail with 200 ll of pristane or alkane (C8–C17) oils.
Collagen-induced arthritis (CIA) was induced by a SC
injection of 100 ll of rat collagen type II (CII) (100–150 lg/
rat), puriﬁed from the Swarm rat chondrosarcoma as
previously described [15], emulsiﬁed in IFA (Difco, BD
Diagnostic Systems, Maryland, United States).
Nonoil collagen-induced arthritis (NOCIA) was induced by
emulsifying rat CII (300 lg) in a mixture of LPS (50 lg; Sigma-
Aldrich), CPG (59-TCC ATG ACG TTC CTG ACG TT-39) (45
lg; MWG-Biotech AG, Ebersberg, Germany), and alum (6 mg;
Sigma-Aldrich) and injected SC in a total volume of 300 ll.
Arthritis development was monitored with a macroscopic
scoring system of the four limbs ranging from 0 to 15 (one
point for each swollen or red toe, one point for midfoot digit
or knuckle, and ﬁve points for a swollen ankle). The scores of
the four paws were added, yielding a maximum total score of
60 for each rat [16].
Treatment of Arthritis
Unless stated otherwise, preventive treatment of arthritis
was performed by SC injections of 200 ll of phytol, C11, or
C16 5 d before induction of arthritis. Control rats were left
untreated.
Therapeutic treatments were administered SC or intra-
peritoneally (IP; 200 ll) after onset of disease in the acute or
chronic phase.
Comparisons to standard treatments were performed by
injection of phytol (200 ll SC), etanercept (generously
provided by Prof. H. Burkhart, Erlangen, Germany; 0.4 mg/
kg in PBS SC), or MTX (Wyeth Lederle, Solna, Sweden; 0.1–
0.25 mg MTX/kg rat IP) on days 8, 10, and 12 in a total volume
of 200 ll.
Treatment of adoptive transfer was performed by injecting
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Oxidation Therapy for Arthritis200 ll of phytol SC in the recipients 3 h before or 3 or 5 and 8
d after transfer. Donor rats were treated with 500 ll of phytol
SC on days  5, 0, 3, 7, or 10 (3 h before spleen isolation).
Determination of Oxidative Burst Activity Ex Vivo
The level of intracellular oxidative burst ex vivo was
measured by preparing single-cell suspensions from blood,
spleen, draining lymph nodes (LNs), or bone marrow (BM).
Red blood cells were lysed with ammonium chloride (pH 7.4)
at a concentration of 0.84%.
Oxidative burst in granulocytes and T cells was determined
by incubation of cells for 30 min at 4 8C with biotin-labelled
antibody HIS-48 (anti-granulocytes) or PerCP-labelled R73
antibody (anti-T cell receptor) (BD Biosciences Pharmingen,
San Jose, California, United States). After they were washed
with PBS, cells were incubated with allophycocyanin-con-
jugated streptavidin (BD Pharmingen) for 20 min at 4 8C. To
determine the level of NADPH activity we used a modiﬁed
version of the oxidative burst activity ﬂow cytometry assay
previously described [17]. Brieﬂy, cells were resuspended in
Dulbecco’s complete medium without FCS after staining, and
incubated for 10 min at 37 8C with 3 lM dihydrorhodamine-
123 (Molecular Probes, Leiden, The Netherlands), which, after
oxidization by hydrogen peroxide (H2O2), peroxinitrite
(ONOO
 ) and hydroxyl radicals (OH ) to rhodamine-123,
emits a bright ﬂuorescent signal upon excitation by blue light.
Cells were then stimulated with 200 ng/ml phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich) for 20 min at 37
8C. After a wash with PBS they were acquired on a FACSort
(BD Biosciences), gated on cell-type. R-123 ﬂuorescence
intensity was measured on FL-1 and results expressed in
relative ﬂuorescence units.
Lipid Peroxidation
Blood was collected in nonheparinized tubes and serum
was isolated by centrifugation. The level of lipid peroxidation
was measured by a modiﬁed version of the malonedialde-
hyde-thiobarbituric acid method previously described [18]. In
brief, a 1:1:1 mixture containing thiobarbituric acid (3.75g/l;
Sigma-Aldrich), TCA (15%), and HCl (0.33 M) was freshly
prepared. 3 ll of 2,6-di-tert-butyl-4-methylphenol (2% in
ethanol) was added to 100 ll of serum together with 200 llo f
the reaction mix and mixed vigorously. The samples were
then incubated for 25 min at 95 8C and centrifuged at 13,000
rpm for 5 min. The absorbance of the supernatant was then
measured at 536 nm in a Spectra Max (Molecular Devices,
Sunnyvale, California, United States).
Ex Vivo Analysis of Lymphocyte Populations
Blood, spleen, and draining LNs were taken from rats 5 d
after SC injection with 200 ll of phytol, and single-cell
suspensions were prepared. Red blood cells were lysed in
0.84% ammonium chloride (pH 7.4) and remaining cells were
washed in PBS before staining with antibodies OX-33 (anti-
CD45RA), OX-35 (anti-CD4), 341 (anti-CD8b), and R73 (anti-
T cell receptor) (all from BD Pharmingen). Cells were
acquired on a FACSort (BD Biosciences) and B-to-T cell
ratio as well as CD4/CD8 ratio were determined after gating
on respective cell type.
Total IgG and IgM Levels
In order to determine total antibody level, plates (Max-
iSorp, Nunc, Roskilde, Denmark) were coated with anti-IgG
(Zymed, San Francisco, California, United States) or anti-IgM
(BD Pharmingen) in PBS overnight. After plates were blocked
for 2 h at room temperature with 1% BSA (Sigma-Aldrich),
plasma diluted in PBS was added. Levels of antibodies were
then detected using biotinylated anti-IgG (Zymed) or anti-
IgM antibody (BD Pharmingen) followed by incubation with
peroxidase-conjugated streptavidin and ABTS tablets (Roche
Diagnostics GmbH, Mannheim, Germany). Results were
analyzed in a Spectra Max at OD 405 nm (Molecular Devices).
The relative amount of antibodies was compared to a pooled
positive control.
Ex Vivo Cell Death Assay
Blood, spleens, and draining LNs were taken from
DA.Ncf1
DA rats 3 h or 5 d after they were injected intra-
dermally with 200 ll of phytol. Single-cell suspensions were
prepared and red blood cells lysed with 0.84% ammonium
chloride (pH 7.4). Cells were washed with PBS, then stained
with OX-35 (anti-CD4) (BD Pharmingen) for 30 min at 4 8C.
Cells were resuspended in 200 ll of PBS containing 5 llo f
Annexin V (BD Pharmingen) and 1 lg/ml of propidium iodide
(PI) (Molecular Probes) after washing. Cells were acquired on
a FACSort (BD Biosciences) and the percentages of apoptotic
(Annexin V
þ and PI




þ cells were determined.
Antibody Response against CII
Antibodies titres against CII in plasma were determined by
ELISA in 96-well plates (MaxiSorp), coated overnight at 4 8C
with 10 lg/ml rat CII in 50 ll of PBS per well. All washing was
performed using PBS containing 0.1% Tween 20. The plasma
was diluted in PBS and analyzed in duplicates. The amounts
of bound IgG antibodies were estimated after incubation with
biotin-conjugated isotype-speciﬁc antibodies (Zymed) fol-
lowed by peroxidase-conjugated streptavidin and ABTS
(Roche Diagnostics) as substrate followed by detection in a
Spectra Max at OD405 nm (Molecular Devices). The relative
amount of antibodies in plasma was determined in compar-
ison with a positive control of pooled serum.
Delayed-Type Hypersensitivity in response to CII
On day 67 after NOCIA immunization, rats were chal-
lenged with 20 lg of CII in 0.05 M acetic acid injected into the
epidermis of the right external ear. Acetic acid was injected
in the left ear as a control. The delayed-type hypersensitivity
(DTH) response was measured after 24 h as the difference in
swelling between the right and left ear in percent.
Determination of Serum Levels of Cartilage Oligomeric
Matrix Protein
The plasma concentration of cartilage oligomeric matrix
protein (COMP) was determined by a competitive ELISA as
described previously [19]. Brieﬂy, rat COMP was used to coat
the microtitre plates and to prepare the standard curve
included in each plate. Plates were blocked with 1% BSA in
PBS before adding plasma. COMP levels were then detected
by using a rabbit polyclonal antiserum against rat COMP
(generously provided by Professor Dick Heinega ˚rd, Lund,
Sweden). The amounts of serum COMP were estimated after
incubation with an alkaline phosphatase-conjugated, isotype-
speciﬁc antibody (DAKO, Glostrup, Denmark) and a phos-
phatase substrate (Sigma-Aldrich), followed by detection in a
SpectraMax (Molecular Devices) at OD 405 nm.
PLoS Medicine | www.plosmedicine.org September 2006 | Volume 3 | Issue 9 | e348 1627
Oxidation Therapy for ArthritisReversion of the Phytol Effect with Histamine
Dihydrochloride
Rats were injected with 200 ll of phytol SC on day 25 after
the induction of disease with an injection of 200 ll of pristane.
At day 35 half of the phytol-treated rats were injected with
histamine dihydrochloride (Sigma-Aldrich) both SC (125 llo f
0.6 mg/ml) and IP (125 ll of 0.6 mg/ml) for a total of 0.15 mg
of histamine dihydrochloride/rat. The same rats were injected
again in the same way on day 40 after pristane. The control
rats were left untreated.
Histological Analysis
DA.Ncf1
DA rats were injected either with phytol and
pristane or with pristane alone on day 0 (200 ll SC). Half of
the pristane-injected rats were treated with 200 ll of phytol
SC day 13. All rats were sacriﬁced day 22 and paws were taken
for histological analysis. The samples were ﬁxed in 4%
phosphate-buffered paraformaldehyde before being decal-
ciﬁed with 1% EDTA and embedded in parafﬁn. Sections
were stained with erythrosine-hematoxylin and magniﬁed
203.
Adoptive Transfer of Arthritogenic Spleen Cells
DA.Ncf1
DA rat spleens were collected and homogenized 10–
14 d after injection of 500 ll of pristane. The red blood cells
were lysed in 0.84% ammonium chloride (pH 7.4) and
remaining cells were washed with PBS before culture in D-
MEM (Gibco) containing concanavalin A (Sigma-Aldrich) for
44 h. After they were washed and resuspended in PBS the cells




Quantitative data are expressed as mean 6 standard error
of the mean, and signiﬁcance analysis was performed using
Mann-Whitney test. All results were compared to those from
the control group unless otherwise indicated.
Results
Oxidative Burst-Inducing Agents Prevent Arthritis
Since low oxidative burst capacity increased arthritis
susceptibility [7], we proposed that substances elevating
ROS production could have therapeutic effects on arthritis.
We had already seen that certain oils with an alkane
structure, such as phytol (3,7,11,15-tetramethyl-2-hexade-
cen-1-ol) and pristane (2,6,10,14-tetramethylpentadecane),
had an oxidative burst-inducing capacity in vitro. Addition-
ally, despite structural similarity, pristane induced arthritis,
whereas phytol protected against it [7]. To examine the
structure/function relationship we screened a number of
short saturated alkanes (C8–C17) using an isoluminol-based
oxidative burst assay [14] on human promyelocytes (HL-60)
differentiated to granulocytes in the presence of DMSO.
Alkanes 11–13 carbons long were the most potent in
activating the NADPH oxidase complex (Figure 1A). To
investigate their arthritogenic potential, we injected the
alkanes into arthritis-susceptible DA rats carrying the DA
Ncf1 allele (Ncf1
DA). Alkanes with 15 carbons or more, such as
pristane, induced arthritis, whereas shorter alkanes did not
(Figure 1B). We therefore concluded that the arthritis-
inducing effect of these oils is independent of their oxidative
burst-inducing capacity.
Next we wanted to see if oxidative burst-inducing effect
Figure 1. Substances Inducing Oxidative Burst In Vitro Prevent Arthritis
(A) Structure of the oil is important for oxidative burst-inducing effect in vitro. Extracellular ROS production was measured with an isoluminol assay on
HL-60 cells after in vitro stimulation with alkanes, phytol (Ph), or pristane (Pr). Data represent one of several experiments.
#Value is divided by 10.
(B) Alkanes longer than C15 induce arthritis. Arthritogenicity of alkanes (n ¼ 4), phytol (Ph; n ¼ 5), and pristane (Pr; n ¼ 7) after SC administration in
DA.Ncf1
DA rats. Results are presented as cumulative incidence in percent.
(C) Oxidative burst-inducing alkanes prevent arthritis. Arthritis-preventing effect of selected alkanes after SC administration day 5 before PIA induction
(control, n ¼ 17; C11, n ¼ 6; and C16, n ¼ 5) in DA.Ncf1
DA rats.
(D) Phytol inhibits development of arthritis. Preventive effect of phytol on PIA in DA.Ncf1
DA rats. Phytol was injected SC day 5 prior to pristane injection
(control, n ¼ 12; phytol, n ¼ 13).
(E) The preventive effect of phytol is dependent on route of administration. Preventive effect of phytol on PIA in DA.Ncf1
DA rats after IP (200 ll), SC (200
ll), or intranasal (25 ll) administration on days  5 and þ5( n ¼ 7).
*p , 0.05, **p , 0.01, ***p , 0.001.
DOI: 10.1371/journal.pmed.0030348.g001
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Oxidation Therapy for Arthritiscorrelated with arthritis prevention using PIA [20] as a model
of human RA. C11, shown to induce oxidative burst in vitro,
was potent in reducing arthritis severity when administered 5
d before arthritis induction (Figure 1C). Similar results were
also seen with C12 and C13 (unpublished data). In contrast,
C16, which was arthritogenic and did not increase oxidative
burst, did not protect against arthritis (Figure 1C). These
results clearly demonstrate that small changes in structure
determine the effect of the molecule. Since phytol was
superior in inducing oxidative burst in vitro as well as in
preventing arthritis when injected before induction of disease
(Figure1Aand1D),itwaschosenforfurtherstudiesofefﬁcacy.
We then investigated the dependency of arthritis-prevent-
ing effects on route of administration. When phytol was
administered SC, IP, or intranasally 5 d before and after PIA
induction it was evident that SC administration resulted in
the best preventive effect (Figure 1E).
Phytol Increases Oxidative Burst Capacity In Vivo
We also wanted to know whether phytol has the same
oxidative burst-inducing effect in vivo. In particular, we asked
whether phytol would correct the low oxidative burst capacity
seen in rats carrying the Ncf1
DA allele. We analyzed spleen
granulocytes 5 d after phytol injection for intracellular
oxidative burst response to PMA stimulation in vitro. Phytol
clearly increased the oxidative burst capacity in DA.Ncf1
DA
rats to the level of the DA.Ncf1
E3 congenic rats carrying the
arthritis-protective E3 Ncf1 allele (Figure 2A). Serum levels of
malondialdehyde, the main product of lipid peroxidation,
were also increased after phytol injection (Figure 2B),
reﬂecting a higher level of oxidation in vivo.
Since a single phytol injection mediated a surprisingly long
suppression of arthritis (Figure 1D) we investigated whether
this protective effect correlated with a sustained increase in
oxidative burst capacity. Thus, we followed the oxidative
burst response to PMA in blood granulocytes for 7 wk after
injection of either pristane or phytol. In order to avoid
intraexperiment variations, results were normalized to a
naı ¨ve standard group. An increase in oxidative burst capacity
was evident the day after phytol (but not after pristane
injection) and persisted for several weeks (Figure 2C). During
development of arthritis the PMA response of pristane-
injected rats increased compared to naı ¨ve rats, possibly
reﬂecting a systemic response to the local inﬂammation; this
ﬁnding agrees with reports of oxygen radicals in synovial
neutrophils in human RA [21].
One possible explanation for the long-lasting effect of
phytol could be that the phenotype of cell populations with
longer lifespans than those of neutrophilic granulocytes, such
as stem cells in BM, is altered. To address this hypothesis we
analyzed BM cells from DA.Ncf1
DA rats 3 and 24 h after
phytol. No effect of injection was seen after 3 h, but 24 h after
administration of phytol the oxidative burst capacity was
elevated up to the level of the protected DA.Ncf1
E3 rats
(Figure 2D).
Increased Oxidative Burst Alters Cell Distribution
Next we investigated the effect of phytol in vivo in blood,
spleen, and draining LNs. Five days after injection, cells from
the different anatomical sites were collected and analyzed for
oxidative burst. Phytol clearly increased the background
activation of granulocytes. Also after PMA stimulation,
phytol-primed granulocytes had a higher response capacity
(Figure 3A), whereas T cells showed only a barely detectable
increase in ROS production (Figure 3B). Compared to the
level of oxidative burst in granulocytes, T cells are minor
producers of ROS (Figure 3C). T cells were also stimulated
with plate-bound anti-CD3, but this did not further increase
the ROS production (Figure S1). The increase in T cell
oxidative burst could be a reﬂection of contaminating ROS
from granulocytes. B/T cell ratio was altered after phytol
injection (Figure 3D), presumably through an increase of B
cell number, because a tendency towards higher levels of IgG
and IgM was also seen (Figure 3E). The same tendency was
seen after phytol treatment in PIA (unpublished data).
Alternatively, the increased B/T ratio could have resulted
from decreased T cell numbers. Phytol did not signiﬁcantly
alter T cell distribution, as no effect on the ratio of CD4/CD8
was seen (unpublished data). To investigate whether the
change in cell distribution was due to phytol toxicity we
analyzed the percentage of apoptotic and necrotic T cells ex
vivo 5 d after injection. Levels of dead T cells did not increase
(Figure 3F), suggesting that the increased B/T ratio or the
Figure 2. Phytol Increases Oxidative Bursts In Vivo
(A) Phytol (Ph) restores the oxidative burst in vivo. Oxidative burst
response to PMA stimulation in vitro in spleen granulocytes taken 5 d
after SC phytol injection in DA.Ncf1
DA rats (200 ll) or from naı ¨ve
DA.Ncf1
E3 compared to naı ¨ve DA.Ncf1
DA (n ¼ 5).
(B) Increased levels of products from lipid peroxidation in serum after
phytol injection. Sera were taken 5 d after SC phytol injection in
DA.Ncf1DA and analyzed for levels of malondialdehyde, which reflects
lipid peroxidation (n ¼ 4).
(C) Phytol injection has a long-term effect on oxidative burst capacity of
granulocytes. Capacity of DA.Ncf1
DA blood granulocytes to exert an
oxidative burst in response to PMA stimulation in vitro after SC injection
of phytol or pristane (200 ll) on day 0. Values are presented as percent of
oxidative burst compared naı ¨ve DA.Ncf1
DA rats (represented by the line)
(n ¼ 5).
(D) Phytol increases the oxidative burst capacity in BM granulocytes.
Oxidative burst capacity of granulocytes from BM taken 3 hours (n ¼ 5)
and 24 hours (n ¼ 4) after SC phytol (Ph; 200 ll) injection in DA.Ncf1
DA
rats or from naı ¨ve DA.Ncf1
E3, compared to naive DA.Ncf1
DA.
#Experiments
were performed independent of each other and levels should thus not
be compared.
*p , 0.05, **p , 0.01.
DOI: 10.1371/journal.pmed.0030348.g002
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Oxidation Therapy for Arthritisdisease-preventing effect is not mediated via increased
depletion of T cells.
Phytol Suppresses CIA and CII Autoimmunity
Since PIA is a model with a unique pathogenesis involving
abT cells, operating in the effector phase as well [20,22], we
analyzed whether phytol operates also in CIA [23], a model in
which antibodies are important in the joint inﬂammatory
attack [24]. A signiﬁcant decrease in arthritis severity
comparable to the effect on PIA was observed after
preventive administration of phytol also in CIA (Figure 4A).
Importantly, phytol suppressed the autoimmune response, as
plasma levels of CII speciﬁc antibodies on day 27 after
immunization were reduced (Figure 4B). Levels of anti-CII of
all isotypes were decreased after phytol treatment; also IgM
response was lower (Figure 4B), suggesting no shift in T cell
response. However, total IgG and IgM levels were not affected
(Figure 4C), arguing for a speciﬁc effect of phytol on CII-
reactive cells. As IgG anti-CII response is T cell-dependent,
these data indicate a lower activity of CII autoreactive T
helper cells.
Phytol Inhibits Arthritis Induced without Adjuvant Oil
So far, arthritis was induced with an oil component such as
pristane or IFA in the CII immunization. To exclude a role of
oil in the induction of disease we developed a new model,
NOCIA. CII was emulsiﬁed in a mixture of nonoil adjuvants,
such as alum, lipopolysaccharide, and a bacterial DNA
sequence (CpG) and injected SC. Phytol injection before
immunization completely blocked the development of disease
(Figure 4D). In addition, when the immune system was
challenged at the end of experiment (day 67 after NOCIA
induction) by a CII injection in the ear, we found that phytol
totally inhibited the DTH response (Figure 4E).
Phytol Decreases Arthritis Severity in Established Disease
To be considered as a new candidate therapy for RA in
humans, phytol needs to be therapeutically effective in
established arthritis. Thus we tested the efﬁcacy of phytol in
both acute and chronic phases of PIA. To test phytol in the
acute phase, rats were treated twice with 5 d between
injections, starting at the peak of the disease (around day
22). Phytol injection markedly decreased arthritis severity
(Figure 5A). A decrease in circulating COMP—a measure-
ment of ongoing cartilage destruction [19]—occurred after
treatment (Figure 5B). To determine the therapeutic efﬁ-
ciency in the chronic phase of PIA, phytol was injected two
times with 3 d between injections starting when the disease
has passed the ﬁrst phase and relapses were observed (around
day 70). The chronic phase is quite different from the acute
phase and is controlled by a different set of genes [25].
Importantly, a signiﬁcant decrease in arthritis severity in
treated rats was observed (Figure 5C). Our results clearly
show that phytol not only has preventive effects but is
therapeutic all along the disease course. Histopathologic
analysis of paws from rats treated either before or during the
acute phase of PIA revealed an effect on both inﬂammation
and joint destruction (Figure 5D). In sections taken from rats
treated in the acute phase of disease a mild inﬂammation
could be seen together with remnants of earlier, more severe
inﬂammation. Rats treated before onset showed no signs of
inﬂammation.
Phytol-Mediated Arthritis Suppression Is Not Restricted to
the DA Background or the Ncf1
DA Allele
To investigate whether the phytol effect was dependent on
the unique DA genetic background, we induced arthritis in
LEW.1F rats, which also develop a chronic arthritis with high
incidence [26]. LEW.1F rats have a lower oxidative burst than
do the protected DA.Ncf1
E3 rat, caused by the same Ncf1 allele
that is carried by DA.Ncf1
DA [7]. As with DA.Ncf1
DA rats,
LEW.1F rats were also protected from arthritis after a
preventive phytol injection (Figure 5E).
Treatment with oxidative burst inducers was thus far done
by increasing ROS production in DA.Ncf1
DA rats. Next we
wanted to investigate whether rats expressing the Ncf1
E3 allele
could be treated successfully with phytol. Since it has been
shown that one allele of Ncf1
E3 is enough to restore the
oxidative burst and to prevent arthritis in DA.Ncf1
DA rats [7],
we used a DA double congenic rat strain expressing not only
Ncf1
E3/DA but also a congenic fragment on Chromosome 6
Figure 3. Increased Levels of ROS Alter Cell Distributions
(A) The phytol-induced increase in oxidative burst in granulocytes is not
organ specific. Granulocytes taken from blood, LNs, and spleen on day 5
after phytol injection were analyzed for oxidative burst with and without
PMA stimulation (n ¼ 5).
(B) Phytol increases oxidative burst in T cells with or without PMA
stimulation 5 d after injection (n¼5). (A) and (B) are taken from different
experiments and levels should thus not be compared.
(C) ROS production in T cells is low compared to that in granulocytes.
ROS production with and without PMA stimulation in spleen granulo-
cytes and T cells from a naı ¨ve DA.Ncf1
DA rat.
(D) Cell distribution is altered after phytol. Cell distribution in different
organs analyzed 5 d after phytol by staining for B and T cells (n ¼ 5).
(E) The phytol effect is not mediated by a general immune-suppressive
effect. Total levels of IgG and IgM antibodies in plasma measured 5 d
after phytol injection expressed as relative values (n ¼ 5).
(F) Phytol does not increase cell death. Percentage of apoptotic (Annexin
Vþ and PI ) and necrotic (Annexin Vþ and PIþ) CD4
þ cells ex vivo 5 d
after phytol injection (n ¼ 5).
*p , 0.05, **p , 0.01.
DOI: 10.1371/journal.pmed.0030348.g003
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treatment in acute phase of disease resulted in a signiﬁcant
decrease in disease severity (Figure 5F). These are important
ﬁndings indicating that phytol can also be therapeutic in
individuals with a ‘‘normal’’ oxidative burst capacity.
Phytol-Induced Suppression of Arthritis Is Reversible
An important issue for a new therapy is whether the effect
is reversible. We selected histamine, which blocks oxidative
burst response in granulocytes in vivo [27]. When histamine
dihydrochloride was injected, the ameliorating effect of
phytol on arthritis severity was reversed (Figure 5G), further
highlighting the importance of ROS for the therapeutic
effect.
Efficiency of Phytol Is Comparable to Standard Treatments
MTX is often the ﬁrst choice of therapy for RA and is in
many cases used in combination with blockers of tumour
necrosis factor-a, a key cytokine in RA [28–30], such as
etanercept. We ﬁrst compared the efﬁciency of phytol and
etanercept in the CIA model, in which tumour necrosis
factor-a blockers previously have shown good effects in rats
[31]. Both phytol and etanercept (administered SC on days 8,
10, and 12) were highly effective in reducing CIA (Figure 6A).
In the PIA model, the prevention mediated by phytol was
even more pronounced than that of etanercept (Figure 6B).
Furthermore, no signiﬁcant reduction of disease severity
could be seen after a single etanercept administration at this
stage of disease, while phytol signiﬁcantly lowered the disease
scoring (unpublished data). Also in comparison to MTX,
phytol was valid as a potential therapeutic agent (Figure 6C).
Phytol Inhibits Arthritogenic T Cells
Phytol was effective at different stages of arthritis. Thus we
wanted to investigate if phytol actually operates in stage-
speciﬁc ways rather than through long-term effects. It is
possible to address this question since PIA is transferable by T
cells. We have shown that when spleen cells are collected 10 d
after pristane administration and cultured in presence of
concanavalin A before transfer to recipient rats, the
arthritogenic cells are CD4
þ abT cells [22] introducing a
good tool for studying the effect of increased oxidative burst
on these cells.
To address the question of whether phytol has a preventive
or therapeutic effect on adoptively transferred PIA, we
pretreated the recipient rats before or after transfer of
arthritogenic T cells. We found equally good preventive
results against arthritis with these treatments (Figure 7A and
7B). Additionally, we wanted to know whether phytol had an
effect on in vivo activation of arthritogenic T cells. Therefore,
donor rats were treated with phytol prior to spleen isolation.
An almost complete blockage of disease could be seen in rats
Figure 4. Phytol Suppresses Type II Collagen Autoimmunity
(A) Phytol prevents collagen-induced arthritis in DA.Ncf1
DA rats. Effect of SC administration of phytol (200 ll) 5 d before immunization with CII (n¼7).
(B) Phytol decreases anti-CII antibody levels in plasma. At day 27 after immunization, plasma samples were taken and analyzed for anti-CII IgG and IgM
levels (n ¼ 7). Titres are relative to pooled positive plasma (units).
(C) Phytol does not decrease total antibody levels. Total levels of IgG and IgM in plasma taken day 27 after immunization compared to pooled positive
plasma (n ¼ 7).
(D) Phytol reduces arthritis severity also in NOCIA, an arthritis model induced without involvement of oil. Preventive effect on arthritis of phytol injection
(200 ll SC) 5 d prior to induction of NOCIA in DA.Ncf1
DA rats (control n ¼ 7; phytol n ¼ 8).
(E) DTH response is abolished after phytol injection. Day 67 after NOCIA immunization the immune system was challenged by an injection of CII in the
ear. Subsequent increase in ear volume was measured and compared to control ear (control n ¼ 7; phytol n ¼ 8).
*p , 0.05, **p , 0.01.
DOI: 10.1371/journal.pmed.0030348.g004
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(Figure 7C), suggesting a phytol-mediated inhibition of
arthritogenic T cells.
To determine when this inhibitory effect on the arthrito-
genic T cells is important, we injected phytol in the donor at
different time points after pristane, i.e. at days 0 (following
pristane injection), 3, 7, and 10 (3 h before sacriﬁce). When
donor splenocytes were analyzed for oxidative burst on day
10, rats given phytol up to 3 d before sacriﬁce had a higher
level of intrinsic oxidative burst (without PMA stimulation in
vitro) (Figure 7D). No difference in oxidative burst was seen
after PMA stimulation, possibly due to the proximity to
arthritis onset (unpublished data). Interestingly, none of the
rats receiving cells from phytol-treated donors developed
arthritis, even if the phytol treatment was given as late as 3 h
before sacriﬁce (Figure 7E). Together with the observation
that no increase in oxidative burst capacity occurred in
spleen cells from these rats, this argues that ROS-producing
cells affect the arthritogenic T cells in vitro, or that the
NADPH oxidase activation is transferred to the recipient.
Figure 5. Phytol Suppresses Established Arthritis
(A) Phytol injection ameliorates acute arthritis. Therapeutic effect of phytol in acute phase of PIA in DA.Ncf1
DA rats after two injections (200 ll) 5 d apart
(arrows) starting at the estimated peak of disease (day 22). (Significance indications above line represent SC administration and below IP administration)
(control n ¼ 18, IP n ¼ 17, and SC n ¼ 16).
(B) Cartilage destruction is decreased after phytol injection. Plasma were taken day 38 and analyzed for COMP levels as a measurement of cartilage
destruction. Results are presented as circles, where each circle represents one individual and filled circles represent rats with a mean reduction in score
after day of first treatment (day 22). Lines represent mean values.
(C) Phytol decreases arthritis severity in the chronic phase of arthritis. Phytol was injected IP twice (200 ll) (arrows), starting day 70 after pristane
injection in DA.Ncf1
DA rats with 3 d between treatments (control, n ¼ 19; phytol, n ¼ 18).
(D) Phytol affects macroscopic and microscopic inflammation. Pristane-injected rats treated with phytol on either day 0 or day 13 (n¼4). On day 22 rats
were sacrificed and paws taken for histology and stained with erythrosine-hematoxylin (photomicrographs to right of graph; 203 magnification).
(E) The preventive effect of phytol is not dependent on genetic background. Arthritis-preventing effect of phytol when injected (200 ll SC) 5 d before
induction of PIA in LEW.1F rats (n ¼ 9).
(F) Phytol has an arthritis-ameliorating effect in rats that have a functional oxidative burst. Rats heterozygous for the functional Ncf1 (Ncf1
E3) allele with
an arthritis susceptibility locus on Chromosome 6 were injected IP (200 ll) with phytol at the estimated peak of disease (day 24, arrow; control, n¼13;
phytol, n ¼ 15).
(G) Histamine dihydrochloride reverses the ameliorating effect of phytol, possibly by blocking oxidative burst. Injection of histamine twice (200 llS C
and IP), with 5 d between injections (arrows), starting 10 d after phytol treatment (day 26 after pristane) in DA.Ncf1
DA rats could reverse the arthritis-
ameliorating effect (n ¼ 5). Results are presented as difference in score compared to day of treatment (day 0).
*p , 0.05, **p , 0.01, ***p , 0.001.
DOI: 10.1371/journal.pmed.0030348.g005
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d after transfer, no differences were seen (unpublished data)
and when the recipient rats were reimmunized with pristane,
all groups developed arthritis (unpublished data) excluding
transfer of regulatory T cells.
To further exclude the inﬂuence on T cells by oxidative
burst-producing cells in vitro, we mixed cells, before culture,
from control rats and rats treated on day 0. Rats transferred
with cells from this mix did develop arthritis (Figure 7E),
although only half the number of arthritogenic T cells were
transferred, suggesting that this is the dominant phenotype.
To exclude an apoptosis-inducing effect, we analyzed blood,
spleens, and draining LNs for cell death 3 h after phytol
injection. Apoptosis did not increase after phytol, in agree-
ment with data from 5 d after treatment. Phytol even seemed
to protect from necrosis (Figure 7F), excluding an acute cell
death-inducing effect of the treatment. This experiment
clearly shows that phytol exercises a rapid regulatory effect
on arthritogenic T cells in both priming and secondary
activation stages in vivo.
Discussion
Our results showing that arthritis suppression is mediated
by increased oxidative burst in vivo open up a chronic
inﬂammatory disease pathway that is possible to target
therapeutically. This new therapeutic approach is based on
reversing a phenotype caused by a genetic polymorphism
responsible for increased severity of arthritis in both rats and
mice [7,32], increasing the possibility that it also operates
similarly in humans. The ROS-inducing compound phytol
showed comparable or better therapeutic effects in compar-
ison with two of the major drugs used for RA today, i.e.,
etanercept and MTX, further conﬁrming its possible ther-
apeutic efﬁcacy. Phytol successfully ameliorated arthritis not
only in rats with low ROS production but also in rats with
normal oxidative burst response, in rats with a different
genetic background, and in different models such as PIA,
CIA, NOCIA, and adoptive transfer models. Taken together
these data suggest that several subtypes of the heterogeneous
disease RA could be treated using this approach.
Generally, ROS is thought to play a major role in defence
against invading pathogens. A complete lack of ROS due to
Ncf1 deﬁciency results in chronic granulomatous disease in
both mice [33] and humans. Patients with chronic granulom-
atous disease suffer not only from a granulomatous inﬂam-
matory disease but also from increased susceptibility to
infections. The observed increased arthritis severity in low
burst-responding rats could be inﬂuenced by increased
infection susceptibility. We believe that this is not the case,
as we did not observe any pathogenic infections in the rats.
Also preliminary data suggest that mice with an Ncf1
mutation showed similar arthritis susceptibility in both
conventional and SPF conditions (unpublished data). Most
likely, the investigated Ncf1 polymorphism have different
effects as compared with the complete Ncf1 deletion causing
chronic granulomatous disease.
Recently ROS has been thought not only to act on invading
pathogens but also to play an important regulatory role in the
immune system. Although granulocytes are the main ROS-
producing cell type, a preventive effect on arthritogenic T
cells could clearly be seen after treatment. This preventive
effect could be mediated at several different stages. It has
been shown that coincubation of T cells with ROS-producing
granulocytes inhibits cytokine production [34]. Also, T cell
expansion [35] and apoptosis [36] are affected by altered
levels of oxygen radicals. The increased ROS production seen
after phytol treatment could in addition change the general
oxidation status of T cells and thereby mediate suppression.
Oxidation of proteins on cell surfaces has been shown to be
crucial for function, e.g., the protein LAT (linker for
activation of T cells) is highly sensitive to redox alterations,
resulting in lower T cell receptor signalling after oxidation
[37]. A reducing environment has also been shown to be
important for T cell proliferation [38]. T cells have themselves
been proposed to express the components of the NADPH
oxidase complex and to produce ROS [39]. We measured an
increased oxidative burst in T cells after phytol treatment,
but to a dramatically lower level than that of granulocytes.
This increased ROS could be a result of ROS leaking from
surrounding granulocytes or produced by other oxidative
burst mechanisms independent of Ncf1. We could not
exclude, however, the possibility that the T cell oxidative
Figure 6. Phytol Is as Effective as or More Effective than Standard
Treatments for RA
(A, B) Comparison of efficacy of phytol and etanercept in (A) CIA (n ¼ 8)
and (B) PIA (n ¼ 7) in DA.Ncf1DA rats. 200 ll of phytol and 0.4 mg/kg
etanercept in a total volume of 200 ll was injected (SC) on days 8, 10,
and 12 after disease induction.
(C) Efficacy of phytol and MTX. MTX (IP) and phytol (SC) was injected on
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to be regulated by ROS produced extracellularly from other
cells, such as the Ncf1-dependent activities of antigen-
presenting cells and granulocytes, as well as by internal
mitochondrial activities. For example, protein tyrosine
phosphatases, regulators of a wide array of cellular signalling
pathways, can be inactivated by oxidation [40], which is
interesting because a polymorphism in PTPN22 has been
shown to be associated with several chronic inﬂammatory
diseases, including RA [41]. This mutation leads to a more
potent negative effect on T cell receptor signalling akin to
what can be envisioned by a reduced cysteine in the
combining site of the protein tyrosine phosphatases.
ROS can also directly act as a second messenger in
signalling pathways—for example, in the Raf-1/extracellular
signal-regulated protein kinase signalling cascade [42]—or
the effect of phytol could be mediated indirectly. It has been
shown that oxidized phospholipids could block Toll-like
receptor-mediated activation of dendritic cells [43] and
macrophages [44], limiting their capacity to stimulate T cells,
thereby suggesting a regulatory feedback mechanism.
The increase in oxidative burst after phytol was not
restricted to one anatomical compartment and was observed
in blood, BM, spleen, and LNs. Thymus could also be affected
by this treatment. Altered oxidation status could affect the
depletion of autoreactive T cells and the activation threshold
of autoreactive T cells, resulting in a lower level of
autoreactivity. Ultimately, phytol affected development of
arthritogenic T cells very rapidly. As early as 3 h after phytol
injection it was no longer possible to transfer disease from
pristane-injected rats. The arthritis-preventive effect in
adoptive transfer probably operates through down-regula-
tion of arthritogenic T cells and is not mediated by ROS-
producing cells in vitro or in the recipient, since the mix of
treated and untreated cells transferred arthritis, and no
alterations of oxidative burst occurred in the recipient after
transfer. The early preventive effect seen after phytol is likely
not mediated via induction of oxidative burst in T cells, since
the effect is lost in phytol-primed T cells cultured together
with arthritogenic T cells. These ﬁndings also exclude
transfer of regulatory T cells, since recipients developed
PIA in a normal manner.
Figure 7. Phytol Inhibits Arthritogenic T Cells In Vivo
(A) Phytol (Ph) prevents adoptive transfer of arthritis when injected into the recipient DA.Ncf1
DA rat before onset. Phytol was injected (200 ll SC) in the
recipient 3 d or 3 h before transfer of arthritogenic T cells from pristane injected DA.Ncf1
DA rats (control, n ¼ 8; phytol, n ¼ 16).
(B) Phytol ameliorates arthritis also when injected in recipient DA.Ncf1
DA rats after disease onset. Phytol was injected (200 ll SC) in the recipient rats
days 5 and 8 after transfer of arthritogenic T cells (control n ¼ 7 and phytol n ¼ 8).
(C) Phytol inhibits arthritogenic T cells when injected in the donor DA.Ncf1
DA rat. Spleen cells from phytol treated (500 ll SC day 5) rats were taken day
10 after pristane injection, transferred into naı ¨ve DA.Ncf1
DA rats and the effect of phytol on the development of arthritogenic T cells were followed
(n ¼ 8).
(D, E) Phytol has a rapid inhibitory effect on arthritogenic T cells. The time-point for the effect of phytol was titrated by administration of phytol (500 ll
SC) on different days after pristane injection (day 0). Day 10 after pristane, donor spleens (DA.Ncf1
DA) were taken and analyzed for oxidative burst of
granulocytes (n¼3) (D) and the cells transferred into naı ¨ve DA.Ncf1
DA recipient rats. The rats were then monitored for arthritis symptoms (E). Cells from
rats treated day 0 and control rats were also mixed (50:50) to investigate a possible dominating effect of phytol treatment (control [Cnt], n¼6; phytol,
n ¼ 5; and mix, n ¼ 3).
(F) Phytol does not induce acute cell death. Percentage of apoptotic (Annexin Vþand PI ) and necrotic (Annexin Vþand PIþ) CD4
þcells ex vivo 3 h after
phytol (n ¼ 5).
*p , 0.05, **p , 0.01, ***p , 0.001.
DOI: 10.1371/journal.pmed.0030348.g007
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established arthritis through a previously little-studied path-
way involving a protective oxidative burst. The treatment was
effective in different arthritis rat models, different rat strains,
and at different stages of the disease regulated by different
genes and mechanisms. Thus, phytol represents a promising
new class of pharmaceuticals to further investigate for
treatment of chronic inﬂammatory diseases.
Supporting Information
Figure S1. Anti-CD3 Stimulation of T Cells from Naı ¨ve and Phytol-
Injected DA.Ncf1DA Rats
Cells were taken from different anatomical sites 5 d after phytol
injection. Following lysis of red blood cells, remaining cells were
stained for T cell receptor with R73 then incubated with plate-bound
anti-CD3 (G4.18) in the presence of DHR-123. Cells were analysed for
R-123 by FACS (n ¼ 5). *p , 0.05.
Found at DOI: 10.1371/journal.pmed.0030348.sg001 (194 KB JPG).
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Background. Rheumatoid arthritis (RA) is a chronic illness that affects
between 0.3% and 1% of people worldwide, causing pain and swelling in
joints, tendons, and other tissues, and frequently leading to permanent
deformity and disability. RA involves an abnormal attack by cells of the
immune system against the body’s own connective tissues (so-called
autoimmunity). Current drugs for RA work by counteracting the
molecules that cause the pain and swelling (inflammation). By reducing
the severity of autoimmune inflammation, these drugs may also reduce
the disease’s long-term damage to joints.
Inflammation is not always abnormal, but in fact plays an important
part in the body’s defense against infection. As part of their activity
against disease-causing bacteria, the white blood cells known as
granulocytes generate reactive oxygen species (ROS), sometimes known
as ‘‘free radicals.’’ After engulfing invading bacteria, neutrophils release
an ‘‘oxidative burst’’ of ROS—essentially the subcellular equivalent of
pouring hydrogen peroxide on a wound to disinfect it. A complex of
molecules known collectively as the NADPH oxidase complex has the
specific function of generating ROS to fuel the oxidative burst.
Interestingly, recent experiments in arthritis-prone rats found that
animals with an altered form of one of the subunits of this complex,
Ncf1, that decreased the production of ROS also had greater suscept-
ibility to arthritis. This finding was surprising because free radicals have
generally been associated with inflammation and long-term damage to
cells, so that a reduction in ROS might have been expected to decrease
susceptibility to an inflammatory disease like RA.
Why Was This Study Done? Because many patients with autoimmune
inflammatory illnesses like RA do not respond to currently available
therapies, new approaches to treatment merit investigation. Based on
the observed association between reduced ROS and increased suscept-
ibility to arthritis, the researchers wanted to find out whether treatment
with a compound that increases ROS production by the NADPH oxidase
complex would cause an improvement in arthritis.
What Did the Researchers Do and Find? The researchers tested a
compound called phytol in arthritis-prone rats to see how it affected
inflammation. It is known that arthritis can be induced in these rats by
injecting them with an oil called pristane. The researchers found that
phytol caused a strong oxidative burst in human granulocyte cells grown
in the laboratory, but did not cause arthritis in rats; whereas pristane,
which does cause arthritis, caused a lower oxidative burst in the
granulocytes.
They then studied whether phytol prevented arthritis in rats. They
found that rats injected with phytol were protected from arthritis
following a later injection of pristane. Given this result, they wanted to
know if phytol increased ROS in the rats as it did in laboratory cell
cultures. Studying granulocytes taken from rats that had been treated
with phytol, they found that the oxidative burst of these cells was indeed
increased, and remained increased for several weeks after treatment.
They went on to test phytol as a treatment for active arthritis, and found
that it dramatically reduced swollen joints and destruction of cartilage
when given to rats with acute pristane-induced arthritis.
The beneficial effects of phytol were seen not only in rats bred with
a form of Ncf1 that produces abnormally low amounts of ROS, but also in
rats whose granulocytes produce normal oxidative bursts. When
compared (in rats) to drugs licensed for RA (etanercept and methotrex-
ate), phytol appeared to be at least as effective. The activity of phytol
against arthritis was shown to involve T lymphocytes, as injection of
phytol inhibited transfer of pristane-induced arthritis with these cells.
What Do These Findings Mean? These experiments raise the intriguing
possibility of an entirely new modality for treating autoimmune diseases;
namely, through drugs designed to increase the production of ROS. This
study raises a number of practical and scientific issues. For example, it is
not known whether reduced capacity to produce ROS is a significant
factor in human RA. Also, the connection between ROS production (by
granulocytes) and autoimmune arthritis (which involves activity by T
lymphocytes) remains to be clarified. Finally, the destructive effects
typically associated with free radicals (such as damage to DNA and
blockage of blood vessels) could complicate the use of this approach in
humans, and like any new drugs, those that increase ROS production
might have other, unanticipated side effects. Whatever the outcome of
drug development efforts, however, this study is an excellent reminder
that there are no ‘‘good’’ or ‘‘evil’’ biochemicals—in the intricacies of
cellular metabolism, it’s all a matter of balance.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030348.
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